Transgene et ProBioGen collaborent pour faire progresser le développement des vaccins thérapeutiques individualisés
November 05, 2024 01:30 ET
|
Transgene S.A.
Strasbourg (France), Berlin (Germany), le 5 novembre 2024, 7 h 30 Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies, basées sur des vecteurs...
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
November 05, 2024 01:30 ET
|
Transgene S.A.
Strasbourg (France), Berlin (Germany), November 5, 2024, 7:30 a.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of...
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
September 26, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA and BERLIN, Germany, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against...